Coming back to: The nausea timeline across the first four weeks, with a tabulated log posts 31–50

Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Coming back to post #31, because the follow-up matters more than the original answer.

Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.

Picking up post #31: that is the part I would want checked first.

Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.

Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most prominent in the first 24 to 48 hours after injection and attenuates as the dose is held stable. At each escalation step it often resets briefly before attenuating again.

post #35 is right about the mechanism and I think understates the practical bit.

Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.

I read post #35 twice before replying, because I had assumed the opposite.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Constipation: common, manageable, and frequently under-reported because it is not dramatic. Increasing fibre and fluid intake helps. Over-the-counter management is usually effective. This is worth addressing proactively rather than waiting for it to worsen.

On post #35 — agreed on the reasoning, with one qualification.

Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before attributing all of it to the compound. Some fatigue resolves with time; some persists.

Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site rotation, avoiding reinjection into the same area for weeks, and allowing areas that react to recover all reduce the frequency.

Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound specifically. It is usually self-limiting.

On post #38 — agreed on the reasoning, with one qualification.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training intensity both help preserve lean mass during weight reduction.

Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the first months when weight loss is most rapid.